Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation

British Journal of Ophthalmology

Volumn 80, Issue 4, 1996, Pages 363-366

  Wells, John A ^a   Murthy, Rachna ^b   Chibber, Rakesh ^b   Nunn, Alistair ^b   Molinatti, Pia A ^b   Kohner, Eva M ^b   Gregor, Zdenek J ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOBLOTTING; MALE; PATHOGENESIS; PRIORITY JOURNAL; RETINA MACULA HOLE; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS BODY;

EID: 0029935043     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.80.4.363     Document Type: Article

References (28)

1. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Vis Sci 1948; 68: 137-80.
2. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VE, Dvorak HF. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5.
3. Plouet J, Schilling J, Gospodarowicz D. Isolation of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989; 8: 3807.
4. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
5. Malecaze F, Clamens S, Simmore-Pinatel V, Mathis A, Chollet P, Favard C, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994; 112: 1476-82.
6. Tischer E, Mitchel R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 226: 11947-54.
7. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1309-12.
8. Shaveki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 354: 843-5.
9. Pertovaaram L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 1994; 269: 6271-4.
10. Dvorak HF, Detmar M, Claffey KP, Nagy IA, Vander Waters L, Senger DR. Vascular permeability/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allerg Immunol 1995; 107: 233-5.
11. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986; 446: 5629-32.
12. Miller JW, Shima DT, Tolentino M, Gragoudas ES, Ferrara N, Connolly EJ, et al. Inhibition of VEGF prevents ocular neovascularization in monkey model. Invest Ophthalmol Vis Sci 1995; 36: S401.
13. Thomas MA, Kaplan HJ. Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome. Am J Ophthalmol 1991; 111: 1-7.
14. Gass JDM. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994; 118: 285-98.
15. Grossniklaus HE, Martinez JA, Brown VB, Lambert HM, Sternberg P Jr, Capone AJr, et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992; 114: 464-72.
16. Saxe SJ, Grossniklaus HE, Lopez PF, Lambert HM, Sternberg P, L'Hernault N. Ultrastructural features of surgically excised subretinal neovascular membranes in the ocular histoplasmosis syndrome. Arch Ophthalmol 1993; 111: 88-95.
17. Dastgeib K, Li Q, Chan C-C, Roberge FG, Csaky K, Green WR. Vascular endothelial growth factor (VEGF) in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 1995; 36: S102.
18. Amin RH, Frank RN, Eliott D, Puklin JE. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) immunoreactivity in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1995; 36: S552.
19. Adamis AP, Shima DT, Yeo KT, Brown LF, Berse B, D'Amore PA, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 1993; 193: 631-8.
20. Motokura M, Saito Y, Lim E, Chaudhry NA, Barnstable CJ, Liggett PE. Experimental model of subretinal neovascularization in rats. Invest Ophthalmol Vis Sci 1995; 36: S94.
21. Macular Photocoagulation Study Group. Krypton laser photocoagulation neovascular lesion of age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1990; 108: 109-14.
22. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy after 5 years: results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 109-14.
23. Adamis P, Miller JW, Bernai M-T, D'Amico DJ, Folkman J, Yeo T-K, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50.
24. Plouet J, Chollet P, Pagot V, Chauvaud D, Korobelnik J-F, Favard C, et al. Vasculotropin/VEGF levels in the vitreous of patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci (Suppl) 1992; 33: 1363.
25. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1982; 100: 912-8.
26. Macular Photocoagulation Study Group. Argon laser photocoagulation for ocular histoplasmosis syndrome: results of a randomized clinical trial. Arch Ophthalmol 1983; 101: 1347-57.
27. Macular Photocoagulation Study Group. Argon laser photocoagulation for idiopathic neovascularization: results of a randomized clinical trial. Arch Ophthalmol 1983; 101: 1358-61.
28. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1220-31.